DB16981InvestigationalGene Therapies
Apazunersen is an antisense oligonucleotide designed to target and inhibit the expression of UBE3A-AS. It is being investigated for the treatment of Angelman Syndrome.
- Code names
- GTX-102
Resolves to
Compound
What you can answer from here — as of November 10, 2025
Which companies are running trials of Apazunersen, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account